Lithium chloride increases the production of amyloid-beta peptide independently from its inhibition of glycogen synthase kinase 3 |
| |
Authors: | Feyt Christine Kienlen-Campard Pascal Leroy Karelle N'Kuli Francisca Courtoy Pierre J Brion Jean-Pierre Octave Jean-Noël |
| |
Institution: | Laboratory of Experimental Pharmacology, Université catholique de Louvain, 1200 Brussels, Belgium. |
| |
Abstract: | Glycogen synthase kinase 3 (GSK3) is able to phosphorylate tau at many sites that are found to be phosphorylated in paired helical filaments in Alzheimer disease. Lithium chloride (LiCl) efficiently inhibits GSK3 and was recently reported to also decrease the production of amyloid-beta peptide (Abeta) from its precursor, the amyloid precursor protein. Therefore, lithium has been proposed as a combined therapeutic agent, inhibiting both the hyperphosphorylation of tau and the production of Abeta. Here, we demonstrate that the inhibition of GSK3 by LiCl induced the nuclear translocation of beta-catenin in Chinese hamster ovary cells and rat cultured neurons, in which a decrease in tau phosphorylation was observed. In both cellular models, a nontoxic concentration of LiCl increased the production of Abeta by increasing the beta-cleavage of amyloid precursor protein, generating more substrate for an unmodified gamma-secretase activity. SB415286, another GSK3 inhibitor, induced the nuclear translocation of beta-catenin and slightly decreased Abeta production. It is concluded that the LiCl-mediated increase in Abeta production is not related to GSK3 inhibition. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|